(Albany, US) DelveInsight has launched a new report on Acne Vulgaris Market
DelveInsight’s Acne Vulgaris Market Insights, Epidemiology, and Market Forecast-2030 report delivers an in-depth understanding of the Acne Vulgaris , historical and forecasted epidemiology as well as the Acne Vulgaris market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Acne vulgaris (AV) is a common chronic skin disease involving blockage and/or inflammation of pilosebaceous units (hair follicles and their accompanying sebaceous gland). Acne can present as noninflammatory lesions, inflammatory lesions, or a mixture of both, affecting mostly the face but also the back and chest. AV appears during early puberty when androgenic stimulation triggers excessive production of sebum and abnormal follicular keratinization, colonization by a Gram-positive bacterium (Propionibacterium acnes) and local inflammation.
Request for free sample page:- https://www.delveinsight.com/sample-request/acne-vulgaris-av-market
Acne Vulgaris Treatment
The DelveInsight Acne Vulgaris market report gives a thorough understanding of the Acne Vulgaris by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment. This segment of the report covers the detailed diagnostic methods or tests for Acne Vulgaris. It covers the details of conventional and current medical therapies available in the Acne Vulgaris market for the treatment of the condition. It also provides Acne Vulgaris treatment algorithms and guidelines in the United States, Europe, and Japan.
Acne Vulgaris Market
Acne Vulgaris market is segmented into topical and oral combination treatments. The therapeutic modalities have been designed based on a better understanding of the pathogenesis of acne. In topical therapy, various agents, such as benzoyl peroxide, antibiotics, topical retinoid, etc. can be used as combination medications. Benzoyl peroxide is a mainstay in the over-the-counter treatment of acne vulgaris. It is safe and works by reducing P. acnes colonization without risk of resistance, and low concentrations (2.5%–5%) and can be used with minimal irritation. Topical retinoids remain a fundamental treatment option for clinical acne and continue to be a first-line option for mild-to-moderate acne vulgaris. It expels mature comedones, decrease microcomedone formation, and possess anti-inflammatory properties due to molecular interactions involving Toll-like receptors, nitric oxide, and cytokines. Azelaic acid is another treatment option that has been proven to be as effective against both noninflammatory and inflammatory lesions in topical monotherapy as benzoyl peroxide. Topically, Antibiotics such as macrolides, clindamycin, and erythromycin are used for their bacteriostatic effect on P. acnes as well as their anti-inflammatory properties and are typically used for mild-to-moderate acne.
Acne Vulgaris Report Scope
Table of content
1. Key Insights
2. Executive Summary of Acne Vulgaris
3. Competitive Intelligence Analysis for Acne Vulgaris
4. Acne Vulgaris: Market Overview at a Glance
5. Acne Vulgaris: Disease Background and Overview
6. Patient Journey
7. Acne Vulgaris Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Unmet Needs
10. Key Endpoints of Acne Vulgaris Treatment
11. Marketed Products
12. Emerging Therapies
13. Acne Vulgaris: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Acne Vulgaris
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Why should you buy this report?
Related Reports
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: +919650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/